Hoth Therapeutics, Inc. (HOTH)
NASDAQ: HOTH · Real-Time Price · USD
1.010
-0.030 (-2.88%)
At close: Feb 27, 2026, 4:00 PM EST
1.050
+0.040 (3.96%)
After-hours: Feb 27, 2026, 7:56 PM EST
Hoth Therapeutics Employees
As of December 31, 2024, Hoth Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,961,234
Market Cap
15.67M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - | 2 | 1 |
| Dec 31, 2023 | 3 | 0 | - | 2 | 1 |
| Dec 31, 2022 | 3 | -2 | -40.00% | 2 | 1 |
| Dec 31, 2021 | 5 | 1 | 25.00% | 4 | 1 |
| Dec 31, 2020 | 4 | 2 | 100.00% | 3 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Curis | 34 |
| Citius Pharmaceuticals | 23 |
| BioCardia | 20 |
| IN8bio | 17 |
| Quantum BioPharma | 17 |
| Cocrystal Pharma | 11 |
| Cellectar Biosciences | 11 |
| Iterum Therapeutics | 9 |
HOTH News
- 4 days ago - HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES - PRNewsWire
- 18 days ago - Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model - PRNewsWire
- 18 days ago - EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study - Benzinga
- 23 days ago - Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets - PRNewsWire
- 5 weeks ago - Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients - PRNewsWire
- 5 weeks ago - Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position - PRNewsWire
- 6 weeks ago - Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation - PRNewsWire
- 2 months ago - Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform - PRNewsWire